Trial Profile
A Retrospective Cohort Study Evaluating Treatment Pattern and Associated Costs of Ranibizumab and Aflibercept in Patients With Wet Age-Related macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2014
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Genentech
- 03 Jun 2014 New trial record
- 12 May 2014 According to the Novartis media release, results of this trial presented at the 2014 Association for Research in Vision and Ophthalmology (ARVO) annual meeting.